Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept study of HyQvia in immunoglobulin deficiency with recurrent infections and chronic fatigue syndrome
2016-002370-12Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jul 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Human normal immunoglobulin G in B cell deficiency and myalgic encephalomyelitis (ME), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Improvement in fatigue. Started Jul 2016; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
B cell deficiencymyalgic encephalomyelitis (ME)
Beyond the preview
Go deeper on 2016-002370-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002370-12.